The biopsychosocial effects of restless legs syndrome (RLS)

Neuropsychiatric Disease and Treatment

Volumn 2, Issue 4, 2006, Pages 505-512

  Becker, Philip M ^a  

^a Sleep Medicine Associates of Texas PA   (United States)

Author keywords

Anxiety; Depression; Quality of life; RLS; Treatment

Indexed keywords

AMFEBUTAMONE; ANALGESIC AGENT; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; BENZODIAZEPINE DERIVATIVE; CLONAZEPAM; DOPAMINE RECEPTOR STIMULATING AGENT; GABAPENTIN; LEVODOPA; PERGOLIDE; PLACEBO; PRAMIPEXOLE; ROPINIROLE; SEROTONIN UPTAKE INHIBITOR;

ANXIETY; CLINICAL PROTOCOL; CLINICAL TRIAL; COGNITION; COMORBIDITY; DEPRESSION; DISEASE SEVERITY; DRUG EFFICACY; HEALTH SURVEY; HUMAN; MALAISE; MENTAL HEALTH; MOOD DISORDER; NAUSEA; QUALITY OF LIFE; RESTLESS LEGS SYNDROME; REVIEW; SLEEP DISORDER; SOCIAL PSYCHOLOGY; SOMNOLENCE; SYMPTOM;

EID: 33847252529     PISSN: 11766328     EISSN: None     Source Type: Journal    
DOI: 10.2147/nedt.2006.2.4.505     Document Type: Review

References (58)

1. Abetz L, Allen R, Follet A, et al. 2004. Evaluating the quality of life of patients with restless legs syndrome. Clin Ther, 26:925-35.
2. Agargun MY, Kara H, Ozbek H, et al. 2002. Restless legs syndrome induced by mirtazapine. J Clin Psychiatry, 63:1179.
3. Allen R, Picchietti D, Hening W, et al. 2003. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med, 4:101-19.
4. Allen RP, Earley CJ. 1996. Augmentation of the restless legs syndrome with carbidopa/levodopa. Sleep, 19:205-13.
5. Allen RP, Earley CJ. 2001. Restless legs syndrome: a review of clinical and pathophysiologic features. J Clin Neurophysiol, 18:128-47.
6. Allen RP, Walters AS, Montplaisir J, et al. 2005. Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med, 165:1286-92.
7. Bakshi R. 1996. Fluoxetine and restless legs syndrome. J Neurol Sci, 142:151-2.
8. Banno K, Delaive K, Walld R, et al. 2000. Restless legs syndrome in 218 patients: associated disorders. Sleep Med, 1:221-9.
9. Baseman DG, O'Suilleabhain PE, Reimold SC, et al. 2004. Pergolide use in Parkinson disease is associated with cardiac valve regurgitation. Neurology, 63:301-4.
10. Becker PM, Jamieson AO, Brown WD. 1993. Dopaminergic agents in restless legs syndrome and periodic limb movements of sleep: response and complications of extended treatment in 49 cases. Sleep, 16:713-16.
11. Benes H, Kurella B, Kummer J, et al. 1999. Rapid onset of action of levodopa in restless legs syndrome: a double-blind, randomized, multicenter, crossover trial. Sleep, 22:1073-81.
12. Bogan RK, Fry JM, Schmidt MH, et al. 2006. Ropinirole in the treatment of patients with restless legs syndrome: a US-based randomized, double-blind, placebo-controlled clinical trial. Mayo Clin Proc, 81:17-27.
13. Breslau N, Roth T, Rosenthal L, et al. 1996. Sleep disturbance and psychiatric disorders: a longitudinal epidemiological study of young adults. Biol Psychiatry, 39:411-18.
14. Brown LK, Dedrick DL, Doggett JW, et al. 2005. Antidepressant medication use and restless legs syndrome in patients presenting with insomnia. Sleep Med, 6:443-50.
15. Collado-Seidel V, Kazenwadel J, Wetter TC, et al. 1999. A controlled study of additional sr-L-dopa in L-dopa-responsive restless legs syndrome with late-night symptoms. Neurology, 52:285-90.
16. Connor JR, Boyer PJ, Menzies SL, et al. 2003. Neuropathological examination suggests impaired brain iron acquisition in restless legs syndrome. Neurology, 61:304-9.
17. Corrigan MH, Denahan AQ, Wright CE, et al. 2000. Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress Anxiety, 11:58-65.
18. Desautels A, Turecki G, Montplaisir J, et al. 2002. Evidence for a genetic association between monoamine oxidase A and restless legs syndrome. Neurology, 59:215-19.
19. Desautels A, Turecki G, Montplaisir J, et al. 2001. Dopaminergic neurotransmission and restless legs syndrome: a genetic association analysis. Neurology, 57:1304-6.
20. Ford DE, Kamerow DB. 1989. Epidemiologic study of sleep disturbances and psychiatric disorders. An opportunity for prevention? JAMA, 262:1479-84.
21. Garcia-Borreguero D, Larrosa O, de la Llave Y, et al. 2002. Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study. Neurology, 59:1573-9.
22. Hargrave R, Beckley DJ. 1998. Restless leg syndrome exacerbated by sertraline. Psychosomatics, 39:177-8.
23. Hening W, Walters AS, Allen RP, et al. 2004. Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: the REST (RLS Epidemiology, Symptoms, and Treatment) Primary Care study. Sleep Med, 5:237-46.
24. Hornyak M, Kopasz M, Berger M, et al. 2005. Impact of sleep-related complaints on depressive symptoms in patients with restless legs syndrome. J Clin Psychiatry, 66:1139-45.
25. Kim SW, Shin IS, Kim JM, et al. 2005. Bupropion may improve restless legs syndrome: a report of three cases. Clin Neuropharmacol, 28:298-301.
26. Kushida CA, Allen RP, Atkinson MJ. 2004. Modeling the causal relationships between symptoms associated with restless legs syndrome and the patient-reported impact of RLS. Sleep Med, 5:485-8.
27. Micozkadioglu H, Ozdemir FN, Kut A, et al. 2004. Gabapentin versus levodopa for the treatment of Restless Legs Syndrome in hemodialysis patients: an open-label study. Ren Fail, 26:393-7.
28. Montplaisir J, Boucher S, Poirier G, et al. 1997. Clinical, polysomnographic, and genetic characteristics of restless legs syndrome: a study of 133 patients diagnosed with new standard criteria. Mov Disord, 12:61-5.
29. Mucsi I, Molnar MZ, Ambrus C, et al. 2005. Restless legs syndrome, insomnia and quality of life in patients on maintenance dialysis. Nephrol Dial Transplant, 20:571-7.
30. Pearson VE, Allen RP, Dean T, et al. 2006. Cognitive deficits associated with restless legs syndrome (RLS). Sleep Med, 7:25-30.
31. Phillips B, Young T, Finn L, et al. 2000. Epidemiology of restless legs symptoms in adults. Arch Intern Med, 160:2137-41.
32. Picchietti D, Winkelman JW. 2005. Restless legs syndrome, periodic limb movements in sleep, and depression. Sleep, 28:891-8.
33. Pritchett AM, Morrison JF, Edwards WD, et al. 2002. Valvular heart disease in patients taking pergolide. Mayo Clin Proc, 77:1280-6.
34. Rijsman R, Neven AK, Graffelman W, et al. 2004a. Epidemiology of restless legs in The Netherlands. Eur J Neurol, 11:607-11.
35. Rijsman RM, de Weerd AW, Stam CJ, et al. 2004b. Periodic limb movement disorder and restless legs syndrome in dialysis patients. Nephrology (Carlton), 9:353-61.
36. Rothdach AJ, Trenkwalder C, Haberstock J, et al. 2000. Prevalence and risk factors of RLS in an elderly population. The MEMO study. Neurology, 54:1064-8.
37. Saletu M, Anderer P, Hogl B, et al. 2003. Acute double-blind, placebo-controlled sleep laboratory and clinical follow-up studies with a combination treatment of rr-L-dopa and sr-L-dopa in restless legs syndrome. J Neural Transm, 110:611-26.
38. Saletu B, Anderer P, Saletu M, et al. 2002a. EEG mapping, psychometric, and polysomnographic studies in restless legs syndrome (RLS) and periodic limb movement disorder (PLMD) patients as compared with normal controls. Sleep Med, 3:S35-42.
39. Saletu M, Anderer P, Saletu B, et al. 2002b. EEG mapping in patients with restless legs syndrome as compared with normal controls. Psychiatry Res, 115:49-61.
40. Saletu M, Anderer P, Saletu-Zyhlarz G, et al. 2002c. Acute placebo-controlled sleep laboratory studies and clinical follow-up with pramipexole in restless legs syndrome. Eur Arch Psychiatry Clin Neurosci, 252:185-94.
41. Saletu M, Anderer P, Saletu-Zyhlarz G, et al. 2001. Restless legs syndrome (RLS) and periodic limb movement disorder (PLMD): acute placebo-controlled sleep laboratory studies with clonazepam. Eur Neuropsychopharmacol, 11:153-61.
42. Saletu B, Brandstatter N, Metka M, et al. 1996. Hormonal, syndromal and EEG mapping studies in menopausal syndrome patients with and without depression as compared with controls. Maturitas, 23:91-105.
43. Sanz-Fuentenebro FJ, Huidobro A, Tejadas-Rivas A. 1996. Restless legs syndrome and paroxetine. Acta Psychiatr Scand, 94:482-4.
44. Sevim S, Dogu O, Kaleagasi H, et al. 2004. Correlation of anxiety and depression symptoms in patients with restless legs syndrome: a population based survey. J Neurol Neurosurg Psychiatry, 75:226-30.
45. Silber MH, Ehrenberg BL, Allen RP, et al. 2004. An algorithm for the management of restless legs syndrome. Mayo Clin Proc, 79:916-22.
46. Silber MH, Girish M, Izurieta R. 2003. Pramipexole in the management of restless legs syndrome: an extended study. Sleep, 26:819-21.
47. Trenkwalder C, Garcia-Borreguero D, Montagna P, et al. 2004. Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12 week, randomised, placebo controlled study in 10 European countries. J Neurol Neurosurg Psychiatry, 75:92-7.
48. Trenkwalder C, Stiasny K, Pollmacher T, et al. 1995. L-dopa therapy of uremic and idiopathic restless legs syndrome: a double-blind, crossover trial. Sleep, 18:681-8.
49. Ulfberg J, Nystrom B, Carter N, et al. 2001a. Prevalence of restless legs syndrome among men aged 18 to 64 years: an association with somatic disease and neuropsychiatric symptoms. Mov Disord, 16:1159-63.
50. Ulfberg J, Nystrom B, Carter N, et al. 2001b. Restless legs syndrome among working-aged women. Eur Neurol, 46:17-19.
51. Wagner ML, Walters AS, Fisher BC. 2004. Symptoms of attention-deficit/ hyperactivity disorder in adults with restless legs syndrome. Sleep, 27:1499-504.
52. Walters AS, Ondo WG, Dreykluft T, et al. 2004. Ropinirole is effective in the treatment of restless legs syndrome. TREAT RLS 2: a 12-week, double-blind, randomized, parallel-group, placebo-controlled study. Mov Disord, 19:1414-23.
53. Wetter TC, Brunner J, Bronisch T. 2002. Restless legs syndrome probably induced by risperidone treatment. Pharmacopsychiatry, 35:109-11.
54. Wetter TC, Stiasny K, Winkelmann J, et al. 1999. A randomized controlled study of pergolide in patients with restless legs syndrome. Neurology, 52:944-50.
55. Winkelman JW, Johnston L. 2004. Augmentation and tolerance with long-term pramipexole treatment of restless legs syndrome (RLS). Sleep Med, 5:9-14.
56. Winkelmann J, Prager M, Lieb R, et al. 2005. "Anxietas tibiarum". Depression and anxiety disorders in patients with restless legs syndrome. J Neurol, 252:67-71.
57. Winkelmann J, Wetter TC, Collado-Seidel V, et al. 2000. Clinical characteristics and frequency of the hereditary restless legs syndrome in a population of 300 patients. Sleep, 23:597-602.
58. Zarate CA Jr, Payne JL, Singh J, et al. 2004. Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biol Psychiatry, 56:54-60.